Multidisciplinary management of ovarian germ cell tumours-a single institutional study from India.
chemotherapy
germ cell
ovary
surgery
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
05
2021
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
27
11
2021
Statut:
epublish
Résumé
Ovarian germ cell tumours constitute a heterogeneous group of neoplasm with malignant potential being seen in 5% of cases. There is limited data on treatment outcomes of patients with malignant ovarian germ cell tumours (MOGCT). Here, we present our hospital audit of patients with MOGCT. This is a retrospective data review of patients with MOGCT treated between May 2011 and December 2019. Patients were treated with staging laparotomy and adjuvant chemotherapy, wherever applicable. Surveillance was allowed for those at low risk for recurrence. Clinicopathologic features and treatment details were recorded, and survival analysis was performed. Sixty-five patients with a median age of 25 years (range: 11-52 years) were treated during the study period. The most common histology was immature teratoma in 35.3% of cases. International Federation of Gynecology and Obstetrics stage IC was the most common stage of presentation (47%). Surveillance was advised for 12.3% of cases. Systemic therapy was given in 51 (78%) patients. At a median follow-up of 46 months (range: 1-109 months), the median progression-free survival (PFS) was not reached. Five-year PFS was 79.3% (95% CI: 65.8-88). The most common toxicity was febrile neutropenia (22%) among those who received systemic therapy. Immature teratoma was the most common histology in our series. The majority presented in the early stage. MOGCT is a highly curable disease with surgery and systemic therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian germ cell tumours constitute a heterogeneous group of neoplasm with malignant potential being seen in 5% of cases. There is limited data on treatment outcomes of patients with malignant ovarian germ cell tumours (MOGCT). Here, we present our hospital audit of patients with MOGCT.
MATERIAL AND METHODS
METHODS
This is a retrospective data review of patients with MOGCT treated between May 2011 and December 2019. Patients were treated with staging laparotomy and adjuvant chemotherapy, wherever applicable. Surveillance was allowed for those at low risk for recurrence. Clinicopathologic features and treatment details were recorded, and survival analysis was performed.
RESULTS
RESULTS
Sixty-five patients with a median age of 25 years (range: 11-52 years) were treated during the study period. The most common histology was immature teratoma in 35.3% of cases. International Federation of Gynecology and Obstetrics stage IC was the most common stage of presentation (47%). Surveillance was advised for 12.3% of cases. Systemic therapy was given in 51 (78%) patients. At a median follow-up of 46 months (range: 1-109 months), the median progression-free survival (PFS) was not reached. Five-year PFS was 79.3% (95% CI: 65.8-88). The most common toxicity was febrile neutropenia (22%) among those who received systemic therapy.
CONCLUSION
CONCLUSIONS
Immature teratoma was the most common histology in our series. The majority presented in the early stage. MOGCT is a highly curable disease with surgery and systemic therapy.
Identifiants
pubmed: 34824613
doi: 10.3332/ecancer.2021.1290
pii: can-15-1290
pmc: PMC8580601
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1290Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
None.
Références
Int J Gynecol Cancer. 2001 Jul-Aug;11(4):300-4
pubmed: 11520369
J Surg Oncol. 2008 Aug 1;98(2):111-6
pubmed: 18563734
Br J Cancer. 2011 Aug 9;105(4):493-7
pubmed: 21772335
Lung India. 2020 Mar-Apr;37(2):134-139
pubmed: 32108598
J Clin Oncol. 2004 Oct 1;22(19):3868-76
pubmed: 15302906
Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):347-55
pubmed: 22301054
Eur J Cancer. 2019 May;113:19-27
pubmed: 30954883
Eur J Gynaecol Oncol. 2008;29(6):635-7
pubmed: 19115694
South Asian J Cancer. 2019 Jan-Mar;8(1):35-40
pubmed: 30766850
Crit Rev Oncol Hematol. 2016 Dec;108:128-136
pubmed: 27931830
Gynecol Oncol. 2014 Jan;132(1):28-32
pubmed: 24145115
J Clin Oncol. 2001 Feb 15;19(4):1015-20
pubmed: 11181664
Int J Gynecol Cancer. 2019 Feb;29(2):398-403
pubmed: 30674572
Indian J Surg Oncol. 2018 Jun;9(2):215-219
pubmed: 29887704
Br J Cancer. 2013 Jul 9;109(1):60-7
pubmed: 23660945
Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82
pubmed: 15818867